Tacrolimus liposomal - Lipella Pharmaceuticals

Drug Profile

Tacrolimus liposomal - Lipella Pharmaceuticals

Alternative Names: Intravesical tacrolimus; Liposomal tacrolimus; LP-10

Latest Information Update: 26 Jul 2016

Price : $50

At a glance

  • Originator Lipella Pharmaceuticals
  • Class Lactones; Macrolides
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystitis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cystitis

Most Recent Events

  • 02 May 2017 Lipella Pharmaceuticals plans a phase II trial for Cystitis (Second-line therapy or greater) (Intravesicular) (NCT03129126)
  • 06 May 2016 Preclinical data presented at the Annual Meeting of the American Urological Association (AUA-2016)
  • 13 May 2014 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top